Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTooru Regulatory News (TOO)

Share Price Information for Tooru (TOO)

Share Price is delayed by 15 minutes
Get Live Data
0.17    0.00 (0.00%)
Bid:
0.16
Ask:
0.18
Spread: 0.02 (12.50%)
Market Cap: £3.72m
TOO Live PriceLast checked at - London Stock Exchange

Intraday Tooru Share Chart

Update re Juvela

23 Oct 2025 07:00

RNS Number : 4650E
Tooru PLC
23 October 2025
 

 

 

23 October 2025

Tooru plc

 

("Tooru" or the "Company")

 

Update re Juvela

 

Tooru, a company focused on the health and wellness sector, is pleased to announce that Juvela, the Company's leading gluten free producer, which recently launched its new retail brand, OAF, has now increased the number of products that it currently lists in Tesco to eight under the OAF brand, with week-on-week growth being achieved. At the same time, the Company is in advanced discussions with regard to listing these products with other major supermarket chains.

 

 

 

www.oafglutenfree.co.uk

 

 

The new brand, OAF, is designed to attract a broader healthy foodie shopper in the Free-From aisle. OAF will operate as the Company's strategic retail-facing range, whilst the Juvela brand will continue to occupy its position as a leading coeliac prescription-led offer.

 

Unlike other gluten free brands, which tend to use rice flour, OAF and Juvela products are made using a specially formulated wheat starch with the gluten removed, meaning it is completely safe for a gluten free diet whilst making the taste and texture as close to conventional bread as it gets. Until now this unique process has mainly been used in prescription-coeliac bread offers, but OAF's mainstream brand proposition will open this innovation up to a broader healthy foodie, who may be omitting gluten for lifestyle choices, as well as coeliac consumers.

 

 

 

 

 

 

Juvela has been the most attractive business in the S-Ventures plc ("S-Ventures") portfolio and the main reason for the acquisition of the S-Ventures businesses by the Company which completed earlier this year. Juvela has a well-established market presence which combines a leading coeliac prescription-led product under the Juvela brand with a new product range designed to attract a broader healthy foodie shopper in the Free-From aisle. The previous owners, S-Ventures, in the past received a number of approaches to acquire this business, with a price indication in excess of £10 million for the shares of Juvela. Whilst no current offers are being pursued, this gives the Board confidence as to the value of this business even prior to the launch of OAF.

 

Since relisting, the Company has only raised new funds from the equity placing undertaken at the time and no additional debt has been drawn down under any previously announced debt facilities.

 

Going forward, the Company expects to increase the working capital available for Juvela to support and promote the developing demand for its brands through Juvela's existing funding arrangements.

 

Scott Livingston, CEO said:

 

"We are increasingly confident in the prospects for Juvela and believe that it has significant upside potential. Gluten free consumers - especially the younger, health-conscious segment - are not connecting with brands on the shelf, perceiving them as second best to conventional bread. This presents a significant opportunity to engage this audience with a vibrant, characterful brand that resonates with them, whilst showing how tasty and simple gluten free bread can be through our product innovation.

 

By combining Juvela's historical quality, craft and expertise with OAF's vibrant brand personality, we are on a mission to inject new energy, relevance, taste and enjoyment to the retail Free-From space, starting with a line of high-quality bakery goods, in the fastest growing areas of this category. All of this has been achieved in a relatively short period of time which, we believe, will ultimately create significant value for shareholders."

Enquiries:

 

Tooru plc

Scott Livingston, CEO

 

Tel: +44 (0) 20 3475 0230

Nominated Adviser

Beaumont Cornish

Roland Cornish

Asia Szusciak

Felicity Geidt

 

Tel: +44 (0) 20 7628 3396

 

Joint Broker

Fortified Securities

Guy Wheatley/Mark Wheeler

 

Tel: +44 (0) 20 7186 9950

 

Joint Broker

Shard Capital Partners LLP

Damon Heath/Erik Woolgar

Tel: +44 (0) 20 7186 9950

Joint Broker

Peterhouse Capital Limited

Duncan Vasey/Lucy Williams

Tel: +44 (0) 20 7469 0935

Tel: +44 (0) 20 7469 0936

 

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDDLLFLEBLFFBF
Date   Source Headline
8th Jun 20262:36 pmRNSDirector/PDMR Shareholding
29th May 20267:00 amRNSTermination of proposed acquisition of Mylky
18th May 20267:00 amRNSTrading Update
6th May 20264:36 pmRNSDirector/PDMR Shareholding
16th Apr 20267:00 amRNSTooru agrees in principle to acquire Mylky B.V.
20th Mar 20266:14 pmRNSChange of Registered Office
20th Mar 20269:30 amRNS-RBusiness & Operational Updates
6th Mar 20265:13 pmRNSDirector/PDMR Shareholding
11th Feb 20267:00 amRNSResult of WRAP Offer, Update on Fundraising & TVR
5th Feb 20265:46 pmRNSWRAP Retail Offer
5th Feb 20264:00 pmRNSFundraising, Issue of Equity, PDMR Dealings & TVR
2nd Feb 20267:00 amRNSJuvela update: OAF new listing with major retailer
8th Jan 202610:00 amRNS-RInvestor Webinar – Link to Register
6th Jan 20264:27 pmRNS-RReplacement: Investor Webinar
6th Jan 20261:01 pmRNS-RInvestor Webinar
29th Dec 20257:00 amRNSTrading and financing update, Directorate change
29th Dec 20257:00 amRNSTrading and financing update, Directorate change
10th Nov 20257:00 amRNS-RCorporate Update – Juvela and Pulsin
3rd Nov 20257:00 amRNS-RfocusIR Investor Interview
23rd Oct 20257:00 amRNSUpdate re Juvela
30th Sep 20257:00 amRNSUnaudited Interims for six months to 30 June 2025
18th Aug 202511:09 amRNSChange of Registered Office
17th Jul 20252:30 pmRNSResult of AGM
11th Jul 20258:43 amRNS-RCorporate Update - Juvela
1st Jul 20257:00 amRNSPublication of audited results of S-Ventures plc
23rd Jun 20258:25 amRNSNotice of AGM
19th Jun 20257:00 amRNSFinal Results
5th Jun 20257:00 amRNS-RLaunch of OAF by Juvela
29th May 20253:15 pmRNSHolding(s) in Company
29th May 20259:16 amRNSReplacement Completion, AIM Admission, AIM Rule 26
29th May 20258:00 amRNSReadmission - Riverfort Global Opportunities Plc
29th May 20257:00 amRNSCompletion, AIM Admission, AIM Rule 26 and TVR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.